Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors
- PMID: 11552905
- DOI: 10.1046/j.1365-2036.2001.01050.x
Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors
Abstract
Aim: Proton pump inhibitors taken twice daily before meals (proton pump inhibitor b.d. AC) effectively controls daytime gastric pH; however, nocturnal gastric acid breakthrough (NAB) occurs in more than 75% of patients. Adding an H2-blocker at bedtime decreases NAB in normal subjects. The efficacy of this regimen has not been evaluated in GERD patients. The aim of this study was to assess the effects of proton pump inhibitor b.d., both with and without bedtime H2-blocker on intragastric pH and the occurrence of NAB in GERD patients.
Methods: Prolonged ambulatory pH studies in GERD patients were reviewed. Group A: 60 patients (mean age 53 years, male 30) taking either omeprazole 20 mg or lansoprazole 30 mg b.d. Group B: 45 patients (mean age 49 years, male 23) on proton pump inhibitor b.d. (omeprazole 20 mg or lansoprazole 30 mg) plus an H2-blocker at bedtime (ranitidine 300 mg, famotidine 40 mg or nizatidine 300 mg). Eleven patients were evaluated during treatment with both regimens (group C). The percentage time of nocturnal and daytime intragastric pH > 4 and per cent of patients with gastric NAB were analysed. In the patients with NAB, its duration and associated oesophageal acid exposure also were analysed.
Results: Median percentage time intragastric pH > 4 overnight was 51% in group A, compared to 96% in group B (P < 0.0001). Median percentage daytime pH > 4 was 73% in group A and 79.8% in group B (P=0.14). Median percentage time intragastric pH >p 4 overnight increased from 54.6% without H2RA to 96.5% after adding bedtime H2RA (P=0.0013) in group C patients. NAB occurred in 82% patients in group A and 40% in group B (P < 0.0001). The mean duration of oesophageal acid exposure during NAB was significantly shorter in group B (18 +/- 6 min) than in group A (42 +/- 9 min, P=0.04).
Summary: Adding a bedtime H2-blocker to the treatment enhanced nocturnal gastric pH control and decreased NAB compared to the proton pump inhibitor b.d. regimen. A bedtime H2-blocker also decreased oesophageal acid exposure during NAB.
Conclusion: Adding a bedtime H2-blocker to a proton pump inhibitor b.d. regimen should be considered in patients who require continued nocturnal gastric acid control whilst taking proton pump inhibitor b.d.
Comment in
-
Effects of H2RAs on the control of nocturnal gastric acid breakthrough.Rev Gastroenterol Disord. 2003 Winter;3(1):56-7. Rev Gastroenterol Disord. 2003. PMID: 12684597 No abstract available.
Similar articles
-
Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough.J Clin Gastroenterol. 2008 Jul;42(6):676-9. doi: 10.1097/MCG.0b013e31814a4e5c. J Clin Gastroenterol. 2008. PMID: 18496394
-
Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure.Am J Gastroenterol. 2003 Mar;98(3):545-50. doi: 10.1111/j.1572-0241.2003.07304.x. Am J Gastroenterol. 2003. PMID: 12650785 Clinical Trial.
-
Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.Aliment Pharmacol Ther. 2000 Jun;14(6):709-14. doi: 10.1046/j.1365-2036.2000.00775.x. Aliment Pharmacol Ther. 2000. PMID: 10848653 Clinical Trial.
-
Combination drug therapy for gastroesophageal reflux disease.Ann Pharmacother. 2002 May;36(5):912-6. doi: 10.1345/aph.10247. Ann Pharmacother. 2002. PMID: 11978171 Review.
-
Drugs, bugs, and esophageal pH profiles.Yale J Biol Med. 1999 Mar-Jun;72(2-3):169-72. Yale J Biol Med. 1999. PMID: 10780578 Free PMC article. Review.
Cited by
-
The role of vonoprazan in patients with erosive esophagitis.Therap Adv Gastroenterol. 2022 Sep 13;15:17562848221122623. doi: 10.1177/17562848221122623. eCollection 2022. Therap Adv Gastroenterol. 2022. PMID: 36117573 Free PMC article. Review.
-
Recommendations for the management of cough in adults.Thorax. 2006 Sep;61 Suppl 1(Suppl 1):i1-24. doi: 10.1136/thx.2006.065144. Thorax. 2006. PMID: 16936230 Free PMC article. No abstract available.
-
Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.Therap Adv Gastroenterol. 2018 Jan 9;11:1756283X17745776. doi: 10.1177/1756283X17745776. eCollection 2018. Therap Adv Gastroenterol. 2018. PMID: 29383028 Free PMC article. Review.
-
Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease.J Neurogastroenterol Motil. 2017 Apr 30;23(2):208-217. doi: 10.5056/jnm16087. J Neurogastroenterol Motil. 2017. PMID: 27585842 Free PMC article.
-
Refractory Gastroesophageal Reflux Disease: Diagnosis and Management.J Neurogastroenterol Motil. 2024 Jan 30;30(1):17-28. doi: 10.5056/jnm23145. J Neurogastroenterol Motil. 2024. PMID: 38173155 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical